ECSP15026557A - Compuestos y sus métodos de empleo - Google Patents

Compuestos y sus métodos de empleo

Info

Publication number
ECSP15026557A
ECSP15026557A ECIEPI201526557A ECPI201526557A ECSP15026557A EC SP15026557 A ECSP15026557 A EC SP15026557A EC IEPI201526557 A ECIEPI201526557 A EC IEPI201526557A EC PI201526557 A ECPI201526557 A EC PI201526557A EC SP15026557 A ECSP15026557 A EC SP15026557A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
inhibit glutaminase
cancer
employing
Prior art date
Application number
ECIEPI201526557A
Other languages
English (en)
Inventor
Rene M Lemieux
Jeremy Travins
Janeta Popovici-Muller
Francesco G Salituro
Jeffrey O Saunders
Yongsheng Chen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of ECSP15026557A publication Critical patent/ECSP15026557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Abstract

En la presente se describen compuestos y composiciones que comprenden compuestos que inhiben la glutaminasa. En la presente también se describen métodos para emplear los compuestos que inhiben la glutaminasa en el tratamiento del cáncer.
ECIEPI201526557A 2012-11-22 2015-06-22 Compuestos y sus métodos de empleo ECSP15026557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof

Publications (1)

Publication Number Publication Date
ECSP15026557A true ECSP15026557A (es) 2016-01-29

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201526557A ECSP15026557A (es) 2012-11-22 2015-06-22 Compuestos y sus métodos de empleo

Country Status (36)

Country Link
US (2) US10087172B2 (es)
EP (2) EP2922850B1 (es)
JP (2) JP6333277B2 (es)
KR (1) KR20150085079A (es)
CN (2) CN104936954B (es)
AR (1) AR093598A1 (es)
AU (2) AU2013347771B2 (es)
BR (1) BR112015011830A2 (es)
CA (1) CA2893510C (es)
CL (1) CL2015001392A1 (es)
CR (1) CR20150316A (es)
CY (1) CY1120581T1 (es)
DK (1) DK2922850T3 (es)
EA (2) EA201890754A1 (es)
EC (1) ECSP15026557A (es)
ES (1) ES2690390T3 (es)
HK (1) HK1214593A1 (es)
HR (1) HRP20181628T1 (es)
HU (1) HUE040111T2 (es)
IL (1) IL238958B (es)
LT (1) LT2922850T (es)
MX (1) MX367389B (es)
MY (1) MY177344A (es)
NZ (1) NZ708382A (es)
PE (1) PE20151072A1 (es)
PH (2) PH12015501150B1 (es)
PL (1) PL2922850T3 (es)
PT (1) PT2922850T (es)
RS (1) RS57859B1 (es)
SA (1) SA515360469B1 (es)
SG (2) SG11201504049VA (es)
SI (1) SI2922850T1 (es)
TR (1) TR201812360T4 (es)
TW (2) TWI629268B (es)
UA (1) UA117360C2 (es)
WO (3) WO2014079011A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
BR112015010955A2 (pt) 2012-11-16 2017-07-11 Calithera Biosciences Inc inibidores de glutaminase heterocíclica
KR20150085078A (ko) 2012-11-21 2015-07-22 아지오스 파마슈티컬스 아이엔씨. 글루타마제 억제제 및 사용 방법
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CA2892817A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CN111393431A (zh) 2014-01-06 2020-07-10 理森制药股份公司 谷氨酰胺酶抑制剂
US10000479B2 (en) 2014-03-21 2018-06-19 Agios Pharmaceuticals, Inc. Compounds and their methods of use
US20170050958A1 (en) * 2014-04-30 2017-02-23 Pfizer Inc. Cycloalkyl-Linked Diheterocycle Derivatives
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN107074805B (zh) 2014-07-03 2021-02-26 德州大学***董事会 用于治疗疾病的gls1抑制剂
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
WO2016022969A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
EA035354B1 (ru) 2015-04-06 2020-06-01 Калитера Байосайенсиз, Инк. Лечение рака легких ингибиторами глутаминазы
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017004359A1 (en) 2015-06-30 2017-01-05 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
CN109503570B (zh) * 2015-12-18 2020-08-25 诺言医药科技(上海)有限公司 一种含有索拉非尼的药物组合物及其应用
KR20180095677A (ko) 2015-12-22 2018-08-27 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 (ｒ)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-ｎ-메틸-1ｈ-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
BR112019003533A2 (pt) * 2016-08-25 2019-05-21 Calithera Biosciences Inc. terapia de combinação com inibidores de glutaminase
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
WO2019079632A1 (en) 2017-10-18 2019-04-25 Board Of Regents, The University Of Texas System GLUTAMINASE INHIBITOR THERAPY
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3876928A4 (en) 2018-11-08 2022-08-10 Merck Sharp & Dohme Corp. HISTONE DEACETYLASE INHIBITORS USEFUL IN TREATING OR PREVENTING HIV INFECTION
WO2020191356A1 (en) * 2019-03-21 2020-09-24 Goncalves Marcus Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
ES2152310T3 (es) 1993-03-29 2001-02-01 Basf Ag Derivados de 1-amino-3-fenoxipropano como moduladores de la resistencia a multiples a farmacos.
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
ATE288904T1 (de) * 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
EP1388734B1 (en) 2002-08-01 2004-03-03 MTM Laboratories AG Method for solution based diagnosis
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
AU2001249064A1 (en) 2000-02-22 2001-09-03 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
EP1861715B1 (en) 2005-03-16 2010-08-11 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8716472B2 (en) 2006-10-16 2014-05-06 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
JP5745272B2 (ja) 2007-11-19 2015-07-08 ジェネンテック， インコーポレイテッド 腫瘍進行を阻害するための組成物及び方法
US7951549B2 (en) 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US10532034B2 (en) 2009-03-25 2020-01-14 Cornell University Inhibition of glutaminase C
EP2419177A1 (en) 2009-04-17 2012-02-22 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2011163332A2 (en) 2010-06-23 2011-12-29 University Of Louisville Research Foundation, Inc. Methods for detecting cancer
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
KR102042290B1 (ko) * 2011-11-21 2019-11-07 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제의 헤테로사이클릭 억제제
WO2013138790A1 (en) 2012-03-15 2013-09-19 Research Foundation Of State University Of New York Combination therapies including inhibitors of the extracellular domain of e-cadherin
KR20150085078A (ko) 2012-11-21 2015-07-22 아지오스 파마슈티컬스 아이엔씨. 글루타마제 억제제 및 사용 방법
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
CN111393431A (zh) 2014-01-06 2020-07-10 理森制药股份公司 谷氨酰胺酶抑制剂
US10000479B2 (en) 2014-03-21 2018-06-19 Agios Pharmaceuticals, Inc. Compounds and their methods of use

Also Published As

Publication number Publication date
EA030646B1 (ru) 2018-09-28
JP2016500082A (ja) 2016-01-07
PH12017502141A1 (en) 2019-02-27
UA117360C2 (uk) 2018-07-25
JP6333277B2 (ja) 2018-05-30
IL238958A0 (en) 2015-07-30
CN104936954B (zh) 2018-08-14
EP2922850B1 (en) 2018-07-18
TWI629268B (zh) 2018-07-11
DK2922850T3 (en) 2018-10-08
CL2015001392A1 (es) 2016-04-22
MY177344A (en) 2020-09-13
US20150291576A1 (en) 2015-10-15
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
MX367389B (es) 2019-08-19
AR093598A1 (es) 2015-06-10
AU2013347771A1 (en) 2015-06-11
WO2014079150A1 (en) 2014-05-30
NZ708382A (en) 2020-04-24
TW201906825A (zh) 2019-02-16
TR201812360T4 (tr) 2018-09-21
JP2018150316A (ja) 2018-09-27
CA2893510A1 (en) 2014-05-30
AU2018202954A1 (en) 2018-05-17
BR112015011830A2 (pt) 2017-07-11
CR20150316A (es) 2015-08-28
CN104936954A (zh) 2015-09-23
US20190084976A1 (en) 2019-03-21
TW201427963A (zh) 2014-07-16
CY1120581T1 (el) 2019-07-10
SG11201504049VA (en) 2015-07-30
EA201890754A1 (ru) 2018-08-31
EP2922850A1 (en) 2015-09-30
SA515360469B1 (ar) 2017-07-11
PT2922850T (pt) 2018-10-15
PE20151072A1 (es) 2015-08-26
PH12015501150A1 (en) 2015-08-17
US10689375B2 (en) 2020-06-23
PL2922850T3 (pl) 2018-12-31
EA201590987A1 (ru) 2015-12-30
EP2922850A4 (en) 2016-05-18
SI2922850T1 (sl) 2018-10-30
AU2013347771B2 (en) 2018-02-01
RS57859B1 (sr) 2018-12-31
ES2690390T3 (es) 2018-11-20
EP3456719A1 (en) 2019-03-20
WO2014079136A1 (en) 2014-05-30
CA2893510C (en) 2021-01-19
LT2922850T (lt) 2018-09-10
WO2014079011A1 (en) 2014-05-30
CN108727307A (zh) 2018-11-02
IL238958B (en) 2019-09-26
HRP20181628T1 (hr) 2018-12-14
US10087172B2 (en) 2018-10-02
HUE040111T2 (hu) 2019-02-28
HK1214593A1 (zh) 2016-07-29
PH12015501150B1 (en) 2015-08-17
SG10201609940RA (en) 2016-12-29

Similar Documents

Publication Publication Date Title
ECSP15026557A (es) Compuestos y sus métodos de empleo
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CR20160069A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2015002194A1 (es) Inhbidores de erk y sus usos
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
UY34538A (es) Heteroarilos y usos de los mismos
CL2016003260A1 (es) Profármacos de gemcitabina
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
CL2015003704A1 (es) Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.